119 related articles for article (PubMed ID: 12223043)
1. Will pharmacogenomics alter the role of patents in drug development?
Eisenberg RS
Pharmacogenomics; 2002 Sep; 3(5):571-4. PubMed ID: 12223043
[No Abstract] [Full Text] [Related]
2. [Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry].
Hansen L; Andersen D
Ugeskr Laeger; 2005 May; 167(20):2160-4. PubMed ID: 15987073
[No Abstract] [Full Text] [Related]
3. The role of innovation in drug development.
Drews J; Ryser S
Nat Biotechnol; 1997 Dec; 15(13):1318-9. PubMed ID: 9415870
[No Abstract] [Full Text] [Related]
4. Patent news.
Steele P; Sparrowhawk M
IDrugs; 2004 Apr; 7(4):388-9. PubMed ID: 15125440
[No Abstract] [Full Text] [Related]
5. US patent office, interfering again.
Nat Rev Drug Discov; 2002 Oct; 1(10):750. PubMed ID: 12374105
[No Abstract] [Full Text] [Related]
6. Research tool patents: tips for facing a "pay up now or litigate" ultimatum.
Gogoris A; Ancona P
Nat Biotechnol; 2001 Nov; 19(11):1075-7. PubMed ID: 11689855
[No Abstract] [Full Text] [Related]
7. First round to Amgen in EPO battle.
Robertson D
Nat Biotechnol; 2000 May; 18(5):483. PubMed ID: 10802602
[No Abstract] [Full Text] [Related]
8. Collaborative research presents special problems for patent seekers.
Thorne LW; Ergenzinger ER; Spruill WM
Nat Biotechnol; 2004 Jul; 22(7):901-2. PubMed ID: 15229550
[No Abstract] [Full Text] [Related]
9. Landscape of chromatin control element patents: positioning effects in pharmaceutical bioproduction.
Palazzoli F; Bire S; Bigot Y; Bonnin-Rouleux F
Nat Biotechnol; 2011 Jul; 29(7):593-7. PubMed ID: 21747382
[No Abstract] [Full Text] [Related]
10. Patents on ice.
Stix G
Sci Am; 2004 May; 290(5):48. PubMed ID: 15127661
[No Abstract] [Full Text] [Related]
11. Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney.
Melethil S
AAPS J; 2005 Oct; 7(3):E723-8. PubMed ID: 16353948
[TBL] [Abstract][Full Text] [Related]
12. Implications of pharmacogenomics for drug development and clinical practice.
Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
[TBL] [Abstract][Full Text] [Related]
13. Science and the law. Working through the patent problem.
Walsh JP; Cohen WM; Arora A
Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
[No Abstract] [Full Text] [Related]
14. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
Yan L; Beckman R
Biotechniques; 2005 Oct; 39(10 Suppl):S565-8. PubMed ID: 18957038
[TBL] [Abstract][Full Text] [Related]
15. Encouraging further innovation: Ariad v. Eli Lilly and the written description requirement.
Jakas J
Seton Hall Law Rev; 2012; 42(3):1287-36. PubMed ID: 22803220
[No Abstract] [Full Text] [Related]
16. [Industry of traditional Chinese patent medicine science and technology development and review].
Lu J; Wang F; Yan D; Luo Y; Yang M
Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(1):5-8. PubMed ID: 22741452
[TBL] [Abstract][Full Text] [Related]
17. Enzo Biochem v. Gen-Probe: complying with the written description requirement under US patent law.
Blaug S; Shuster M; Su H
Nat Biotechnol; 2003 Jan; 21(1):97-9. PubMed ID: 12511910
[No Abstract] [Full Text] [Related]
18. Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress.
Li Wan Po A
J Clin Pharm Ther; 2005 Feb; 30(1):1-4. PubMed ID: 15658998
[No Abstract] [Full Text] [Related]
19. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics, genetic tests, and patent-based incentives.
Meurer MJ
Adv Genet; 2003; 50():399-426; discussion 507-10. PubMed ID: 14714702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
